Isabelle Piec

Dr. Isabelle Piec


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2021 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
EEEmma English
Emma English
LCLaura E. Cook
Laura E. Cook
IPIsabelle Piec
Isabelle Piec
SDSamir Dervisevic
Samir Dervisevic
WFWilliam D. Fraser
William D. Fraser
WJW. Garry John
W. Garry John
Background In the initial stages of the SARS-CoV-2 (COVID-19) pandemic a plethora of new serology tests were developed and introduced to the global market. Many were not evaluated rigorously and there is a significant lack of concordance in results across methods. To enable meaningful clinical decisions to be made, robustly evaluated, quantitative serology methods are needed. These should be harmonized to a primary reference material, allowing for the comparison of trial data and improved clinical decision making. Methods A comprehensive evaluation of the new Abbott IgG II anti-SARS-CoV-2 IgG method was undertaken using CLSI based protocols. Two different candidate primary reference materials and verification panels were assessed with a goal to moving towards harmonization. Results The Abbott IgG II method performs well across a wide range of parameters with excellent imprecision (<3.5%) and is linear throughout the positive range (tested to 38,365 AU/mL). The sensitivity (based on ≥14 day post positive RT-PCR samples) and specificity are 98.3% [90.6-100.0%] and 99.5% [97.1-100%] respectively. The candidate reference materials showed poor correlation across methods with mixed responses noted in methods that use the spike protein versus the nucleocapsid proteins as their binding antigen. Conclusions The Abbott IgG II anti-SARS-CoV-2 measurement appears to be the first linear method potentially capable of monitoring the immune response to natural infection, including from new emerging variants. The candidate reference materials assessed do not generate uniform results across several methods and further steps are needed to enable the harmonization process.

16 March 2022 in Current Research in Translational Medicine
Verified
Journal Article
Closed access
IPIsabelle Piec
Isabelle Piec
LCLaura Cook
Laura Cook
SDSamir Dervisevic
Samir Dervisevic
WFWilliam D Fraser
William D Fraser
SRScott Ruetten
Scott Ruetten
WJW Garry John
W Garry John

9 January 2016 in Calcified Tissue International
Verified
Journal Article
Open access
PDF file
IPIsabelle Piec
Isabelle Piec
CWChristopher Washbourne
Christopher Washbourne
Jonathan TangJonathan Tang
Jonathan Tang
EFEmily Fisher
Emily Fisher
JGJulie Greeves
Julie Greeves
WFWilliam D. Fraser
William D. Fraser
Sclerostin, bone formation antagonist is in the spotlight as a potential biomarker for diseases presenting with associated bone disorders such as chronic kidney disease (CDK-MBD). Accurate measurement of sclerostin is therefore important. Several immunoassays are available to measure sclerostin in serum and plasma. We compared the performance of three commercial ELISA kits. We measured sclerostin concentrations in serum and EDTA plasma obtained from healthy young (18–26 years) human subjects using kits from Biomedica, TECOmedical and from R&D Systems. The circulating sclerostin concentrations were systematically higher when measured with the Biomedica assay (serum: 35.5 ± 1.1 pmol/L; EDTA: 39.4 ± 2.0 pmol/L; mean ± SD) as compared with TECOmedical (serum: 21.8 ± 0.7 pmol/L; EDTA: 27.2 ± 1.3 pmol/L) and R&D Systems (serum: 7.6 ± 0.3 pmol/L; EDTA: 30.9 ± 1.5 pmol/L). We found a good correlation between the assay for EDTA plasma (r > 0.6; p < 0.001) while in serum, only measurements obtained using TECOmedical and R&D Systems assays correlated significantly (r = 0.78; p < 0.001). There was no correlation between matrices results when using the Biomedica kit (r = 0.20). The variability in values generated from Biomedica, R&D Systems and TECOmedical assays raises questions regarding the accuracy and specificity of the assays. Direct comparison of studies using different kits is not possible and great care should be given to measurement of sclerostin, with traceability of reagents. Standardization with appropriate material is required before different sclerostin assays can be introduced in clinical practice.

17 February 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
IPIsabelle Piec
Isabelle Piec
EEEmma English
Emma English
MTMary Annette Thomas
Mary Annette Thomas
SDSamir Dervisevic
Samir Dervisevic
WFWilliam D. Fraser
William D. Fraser
WJWilliam Garry John
William Garry John
In the emergency of the SARS-CoV-2 pandemic, great efforts were made to quickly provide serology testing to the medical community however, these methods have been introduced into clinical practice without the complete validation usually required by the regulatory organizations. SARS-CoV-2 patient samples (n = 43) were analyzed alongside pre-pandemic control specimen (n = 50), confirmed respiratory infections (n = 50), inflammatory polyarthritis (n = 22) and positive for thyroid stimulating immunoglobulin (n = 30). Imprecision, diagnostic sensitivity and specificity and concordance were evaluated on IgG serologic assays from EuroImmun, Epitope Diagnostics (EDI), Abbott Diagnostics and DiaSorin and a rapid IgG/IgM test from Healgen. EDI and EuroImmun imprecision was 0.02–14.0% CV. Abbott and DiaSorin imprecision (CV) ranged from 5.2%–8.1% and 8.2%–9.6% respectively. Diagnostic sensitivity of the assays was 100% (CI: 80–100%) for Abbott, EDI and EuroImmun and 95% (CI: 73–100%) for DiaSorin at ≥14 days post PCR. Only the Abbott assay had a diagnostic specificity of 100% (CI: 91–100%). EuroImmun cross-reacted in 3 non-SARS-CoV-2 respiratory infections and 2 controls. The DiaSorin displayed more false negative results and cross-reacted in six cases across all conditions tested. EDI had one cross-reactive sample. The Healgen rapid test showed excellent sensitivity and specificity. Overall, concordance of the assays ranged from 76.1% to 97.9%. Serological tests for SARS-CoV-2 showed good analytical performance. The head-to-head analysis of samples revealed differences in results that may be linked to the use of nucleocapsid or spike proteins. The point of care device tested demonstrated adequate performance for antibody detection.


6 February 2019 in The Journal of Applied Laboratory Medicine
Verified
Journal Article
Open access
PDF file
IPIsabelle Piec
Isabelle Piec
BTBeatrice Tompkins
Beatrice Tompkins
WFWilliam Duncan Fraser
William Duncan Fraser
Asfotase alfa (STRENSIQ®, Alexion Pharmaceuticals, Inc.) is the only approved treatment for patients with pediatric-onset hypophosphatasia, a disease caused by a mutation in the tissue-nonspecific alkaline phosphatase (TNSALP) gene. ALP is often used as signaling system in routine immunoassays. Because asfotase alfa contains the active site of the full ALP enzyme, it can catalyze the substrate as the antibody-conjugated ALP would within an assay. Therefore, its presence in a treated patient’s sample may generate false positive or false negative results. We investigated whether the presence of asfotase alfa within a sample induced interference in immunoassays that utilize ALP or alternative detection systems. Asfotase alfa was added to samples at concentrations from 0.08–5 µg/mL and analysed on various immunoassays following manufacturer’s instructions. Asfotase alfa was detected in all ALP assays but ALKP1 (RayBiotech). We observed no changes in normetanephrine and noradrenaline (IBL) at any asfotase alfa concentration. However, asfotase alfa notably interfered in an oxytocin (ENZO) assay in nonextracted samples. Extraction using a C18 column eliminated the interference. No interference was observed on automated analyzers using alternative detection system (COBAS fT4 and TSH; Advia Centaur FSH, fT4; Architect LH; FSH). Immulite 2000 fT4, TSH, testosterone and hCG (ALP-based) showed no interference. However, the presence of asfotase alfa resulted in a dose-dependent increase of Troponin I signal. The presence of asfotase alfa must be taken into consideration when analyzing blood samples in treated patients to avoid any risk of misinterpretation of false positive/negative results. It is essential that assays be tested for this possible interference.